Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer
Completed · Not applicable
Conditions studied: Breast Cancer
In brief
RATIONALE: Sentinel lymph node biopsy and gene expression profiling of the primary breast tumor may help determine if tumor cells have spread to the axillary lymph nodes and help doctors plan more effective surgery for breast cancer. PURPOSE: This clinical trial is studying how well sentinel lymph node biopsy and primary tumor gene expression profiling work in finding lymph node metastases in women who have received neoadjuvant therapy for stage II, stage III, or stage IV breast cancer.
Key facts
- Study ID
- NCT00080860
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 60
- Starts
- 2004-02-01
- Expected to finish
- 2007-08-01
- Last updated by the study team
- 2012-03-08
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.